Finox Biotech
Biosimilar developer, Switzerland. 1 development product across 1 molecule: follitropin alfa.
First approval in the Atlas: Mar 2014, Bemfola, follitropin alfa (EMA)
FDAproducts approved0
EMAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered1
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Follitropin alfa | Bemfola | · | Mar 2014 | · | · | · | Sep 2016 |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMAMar 2014Bemfola, follitropin alfa
- EDESep 2016Bemfola, follitropin alfa
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.